GlaxoSmithKline Pharmaceuticals Limited
NSE: GLAXO BSE: GLAXO
Prev Close
2906.8
Open Price
2907
Volume
85,191
Today Low / High
2810 / 2919
52 WK Low / High
1872 / 3088
Range
2,675 - 2,956
Prev Close
2909.25
Open Price
2900.05
Volume
7,929
Today Low / High
2808.2 / 2912.5
52 WK Low / High
1877.7 / 3087.95
Range
2,675 - 2,956
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 2815.4 (target range: 2,675 - 2,956), reflecting a change of -91.4 (-3.14435%). On the BSE, it is listed at 2815.65 (target range: 2,675 - 2,956), showing a change of -93.6 (-3.21732%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
GlaxoSmithKline Pharmaceuticals Limited Graph
GlaxoSmithKline Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for GlaxoSmithKline Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 2,815.40, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 2,815.65 | 2,843.81 | 2,559.43 - 3,128.19 |
| 2,871.96 | 2,297.57 - 3,446.36 | ||
| 2,900.12 | 2,030.08 - 3,770.16 | ||
| Bearish Scenario | 2,815.65 | 2,787.49 | 2,508.74 - 3,066.24 |
| 2,759.34 | 2,207.47 - 3,311.20 | ||
| 2,731.18 | 1,911.83 - 3,550.53 |
Overview of GlaxoSmithKline Pharmaceuticals Limited
ISIN
INE159A01016
Industry
Drug Manufacturers - General
Vol.Avg
385,034
Market Cap
476,945,765,016
Last Dividend
44
Official Website
IPO Date
2002-07-01
DCF Diff
-548.87
DCF
3,398
Financial Ratios Every Investor Needs
Stock Dividend of GLAXO
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2024-11-07 | November 07, 24 | 12 | 12 | 2024-11-07 | 2024-11-28 | |
| 2024-05-31 | May 31, 24 | 32 | 32 | 2024-05-31 | 2024-07-28 | |
| 2023-06-30 | June 30, 23 | 32 | 32 | 2023-06-30 | 2023-08-25 | |
| 2022-07-07 | July 07, 22 | 90 | 90 | 2022-07-08 | 2022-08-25 | |
| 2021-07-19 | July 19, 21 | 30 | 30 | 2021-07-20 | 2021-08-26 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 3,441.77 Cr | 1,419.85 Cr | 2,021.92 Cr | 0.5875 | 2.54 Cr | 48.63 Cr | 1,360.20 Cr | 589.96 Cr | 34.83 | 887.30 Cr | 0.1714 |
| 2023-03-31 | 3,251.72 Cr | 1,284.87 Cr | 1,966.85 Cr | 0.6049 | 1.91 Cr | 29.19 Cr | 839.18 Cr | 610.69 Cr | 36.05 | 903.42 Cr | 0.1878 |
| 2022-03-31 | 3,278.03 Cr | 1,449.65 Cr | 1,828.38 Cr | 0.5578 | 1.83 Cr | 42.59 Cr | 769.14 Cr | 380.77 Cr | 22.48 | 848.83 Cr | 0.1162 |
| 2021-03-31 | 3,198.86 Cr | 1,394.67 Cr | 1,804.19 Cr | 0.5640 | 1.81 Cr | 18.47 Cr | 761.49 Cr | 358.15 Cr | 21.14 | 535.63 Cr | 0.1120 |
| 2020-03-31 | 3,224.38 Cr | 1,397.54 Cr | 1,826.84 Cr | 0.5666 | 2.18 Cr | 17.05 Cr | 543.16 Cr | 93.20 Cr | 5.50 | 392.19 Cr | 0.0289 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 64.17 Cr | 3,556.62 Cr | 1,778.98 Cr | 1,777.6397 Cr | 18.67 Cr | -45.51 Cr | 525.05 Cr | 310.73 Cr | 7.55 Cr | 0.00 Cr | 3.42 Cr | 1,524.9461 Cr |
| 2023-03-31 | 34.94 Cr | 3,326.58 Cr | 1,585.30 Cr | 1,741.2800 Cr | 15.54 Cr | -19.40 Cr | 459.97 Cr | 315.12 Cr | 830.29 Cr | -18.20 Cr | -1,764.82 Cr | 1,326.3600 Cr |
| 2022-03-31 | 286.19 Cr | 4,633.28 Cr | 1,970.32 Cr | 2,662.9558 Cr | 20.08 Cr | -266.11 Cr | 534.70 Cr | 325.45 Cr | 4.35 Cr | -18.89 Cr | -2,624.70 Cr | 1,698.4288 Cr |
| 2021-03-31 | 405.19 Cr | 3,113.36 Cr | 1,614.28 Cr | 1,499.0797 Cr | 34.63 Cr | -370.56 Cr | 546.70 Cr | 354.12 Cr | 836.63 Cr | -15.57 Cr | -728.00 Cr | 1,332.4743 Cr |
| 2020-03-31 | 104.81 Cr | 3,135.54 Cr | 1,314.94 Cr | 1,820.6049 Cr | 41.84 Cr | -62.97 Cr | 483.03 Cr | 827.09 Cr | 634.69 Cr | -17.24 Cr | 370.43 Cr | 1,024.2572 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 582.0155 Cr | -84.7206 Cr | -561.4969 Cr | 550.7940 Cr | 29.2303 Cr | 64.1712 Cr | -31.2215 Cr | 589.9610 Cr | -18.1253 Cr | -541.5729 Cr | -65.0778 Cr |
| 2023-03-31 | 484.2300 Cr | 807.8500 Cr | -1,543.3300 Cr | 440.1900 Cr | -251.2500 Cr | 34.9400 Cr | -44.0400 Cr | 841.5000 Cr | 0.0000 Cr | -1,525.4999 Cr | 74.7200 Cr |
| 2022-03-31 | 810.7478 Cr | -405.5076 Cr | -524.2423 Cr | 776.1068 Cr | -119.0021 Cr | 286.1871 Cr | -34.6410 Cr | 2,475.6481 Cr | -0.0240 Cr | -506.6350 Cr | 12.0027 Cr |
| 2021-03-31 | 577.9254 Cr | 418.5916 Cr | -696.1393 Cr | 533.6988 Cr | 300.3777 Cr | 405.1892 Cr | -44.2266 Cr | 723.0952 Cr | -0.1530 Cr | -677.0443 Cr | -46.7930 Cr |
| 2020-03-31 | 490.4997 Cr | -56.8433 Cr | -427.6215 Cr | 334.6016 Cr | 6.0349 Cr | 104.8115 Cr | -155.8981 Cr | 647.2462 Cr | -0.4060 Cr | -408.4559 Cr | -67.7167 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 949.42 Cr | 359.16 Cr | 590.26 Cr | 0.6217 | 273.12 Cr | 229.88 Cr | 13.57 | 326.99 Cr | 0.2421 |
| 2024-09-30 | 1,010.77 Cr | 552.06 Cr | 458.71 Cr | 0.4538 | 304.85 Cr | 252.50 Cr | 14.91 | 360.94 Cr | 0.2498 |
| 2024-06-30 | 814.65 Cr | 462.96 Cr | 351.69 Cr | 0.4317 | 214.13 Cr | 182.33 Cr | 10.76 | 230.54 Cr | 0.2238 |
| 2024-03-31 | 929.80 Cr | 558.06 Cr | 371.74 Cr | 0.3998 | 239.16 Cr | 194.48 Cr | 11.48 | 289.49 Cr | 0.2092 |
| 2023-12-31 | 805.26 Cr | 316.84 Cr | 488.42 Cr | 0.6065 | 229.06 Cr | 45.72 Cr | 2.70 | 82.86 Cr | 0.0568 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 49.26 Cr | 1,000.82 Cr | 2,110.83 Cr | 268.36 Cr | 517.62 Cr | 3,014.35 Cr | 297.64 Cr | 3,745.99 Cr | 2,073.30 Cr |
| 2024-06-30 | -1,856.82 Cr | 3,713.65 Cr | 1,856.82 Cr | 0.00 Cr | 0.00 Cr | 1,856.82 Cr | 0.00 Cr | 0.00 Cr | -1,777.64 Cr |
| 2024-03-31 | 86.08 Cr | 1,792.65 Cr | 1,878.73 Cr | 222.06 Cr | 533.91 Cr | 2,798.42 Cr | 312.26 Cr | 3,573.75 Cr | 1,796.11 Cr |
| 2023-12-31 | -1,605.30 Cr | 3,210.60 Cr | 1,605.30 Cr | 0.00 Cr | 0.00 Cr | 1,605.30 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 73.88 Cr | 1,647.75 Cr | 1,721.63 Cr | 211.07 Cr | 537.44 Cr | 2,499.36 Cr | 314.25 Cr | 3,270.21 Cr | 1,730.66 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 182.33 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 194.48 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 45.72 Cr | 34.22 Cr | 0.00 Cr | 0.00 Cr | 34.22 Cr | 1,125.53 Cr | 1,091.31 Cr | 0.00 Cr | 34.22 Cr |
| 2023-09-30 | 217.51 Cr | 36.22 Cr | 0.00 Cr | 0.00 Cr | 36.22 Cr | 1,091.31 Cr | 1,055.09 Cr | 0.00 Cr | 36.22 Cr |
| 2023-06-30 | 132.25 Cr | 32.72 Cr | 0.00 Cr | 0.00 Cr | 32.72 Cr | 87.76 Cr | 55.04 Cr | 0.00 Cr | 32.72 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2018-09-11 | September 11, 18 | 2:1 |
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,511.10 | ₹1,220,390,199,810.00 | ₹570,127.00 |
| Abbott India Limited | ABBOTINDIA | ₹30,915.00 | ₹656,922,171,330.00 | ₹7,917.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹2,815.40 | ₹476,945,765,016.00 | ₹85,191.00 |
| Gland Pharma Limited | GLAND | ₹1,464.40 | ₹241,269,301,448.00 | ₹333,283.00 |
| Pfizer Limited | PFIZER | ₹4,191.40 | ₹191,747,043,905.00 | ₹21,385.00 |
| Sanofi India Limited | SANOFI | ₹6,306.50 | ₹145,238,695,000.00 | ₹21,446.00 |
| Marksans Pharma Limited | MARKSANS | ₹214.13 | ₹97,035,955,929.00 | ₹626,692.00 |
Key Executives
Gender: male
Year Born: 1977
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: female
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born:
FAQs about GlaxoSmithKline Pharmaceuticals Limited
The CEO is Mr. Bhushan Akshikar.
The current price is ₹2,815.40.
The range is ₹1872-3088.
The market capitalization is ₹47,694.58 crores.
The dividend yield is 1.56%.
The P/E ratio is 55.51.
The company operates in the Healthcare sector.
Overview of GlaxoSmithKline Pharmaceuticals Limited (ISIN: INE159A01016) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹47,694.58 crores and an average daily volume of 385,034 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹44.